# US 2024/0189416 A1 · Stabilized coronavirus spike protein fusion proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189416 A1
- Document ID: US20240189416A1
- Status: Published application
- Kind: A1
- Application number: 17/998,592
- Filed: 2021-05-11
- Published: 2024-06-13
- Earliest claimed: 2020-05-11
- Assignees: Janssen Pharmaceuticals, Inc.
- Applicants: Janssen Pharmaceuticals, Inc.
- Inventors: Jaroslaw JURASZEK; Johannes Petrus Maria LANGEDIJK; Lucy RUTTEN
- Web page: https://patentgrep.com/patent/US20240189416A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C07K 14/165: Coronaviridae, e.g. avian infectious bronchitis virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12Y 304/21075: Furin (3.4.21.75)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/575: {humoral response}
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides stabilized recombinant pre-fusion SARS COV-2 S proteins, nucleic acids molecules encoding the SARS-COV-2 S proteins and uses thereof.

## Claims

### Claim 1

Recombinant pre-fusion SARS-COV-2 S protein, or a fragment thereof, comprising an S1 and an S2 domain, and comprising at least one mutation selected from the group consisting of a mutation of at least one amino acid in the loop region corresponding to amino acid residues 941-945 into P, a mutation of the amino acid at position 892, a mutation of the amino acid at position 614, a mutation at position 572, a mutation at position 532, a disulfide bridge between residues 880 and 888, and a disulfide bridge between residues 884 and 893, wherein the numbering of the amino acid positions is according to the numbering of the amino acid positions in SEQ ID NO: 1.

### Claim 2 (depends on 1)

The protein, or fragment thereof, according to claim 1, comprising an amino acid sequence wherein the amino acid at position 892 is not alanine (A), the amino acid at position 614 is not aspartic acid (D), the amino acid at position 532 is not Asparagine (N) and/or amino acid at position 572 is not threonine (T).

### Claim 3 (depends on 1)

The protein, or fragment thereof, according to claim 1, comprising a mutation of at least one amino acid in the loop region corresponding to amino acid residues 941-945 into P, and a mutation selected from the group consisting of a mutation of the amino acid at position 892, a mutation of the amino acid at position 614, a mutation at position 572, a mutation at position 532, a disulfide bridge between residues 880 and 888 and a disulfide bridge between residues 884 and 893.

### Claim 4 (depends on 3)

The protein, or fragment thereof, according to claim 3, comprising a mutation of at least one amino acid in the loop region corresponding to amino acid residues 941-945 into P, and a mutation selected from the group consisting of a mutation of the amino acid at position 892, a mutation of the amino acid at position 614, a mutation at position 572, a mutation at position 532, a disulfide bridge between residues 880 and 888 and a disulfide bridge between residues 884 and 893, provided that the proteins do not comprise both the disulfide bridge between residues 880 and 888 and the disulfide bridge between residues 884 and 893.

### Claim 5 (depends on 1)

The protein, or fragment thereof, according to claim 1, wherein the disulfide bridge is a disulfide bridge between residues 880 and 888.

### Claim 6 (depends on 1)

The protein, or fragment thereof, according to claim 1, wherein at least one mutation in the loop region corresponding to amino acid residues 941-945 is a mutation of the amino acid at position 942 into P.

### Claim 7 (depends on 1)

The protein, or fragment thereof, according to claim 1, wherein the at least one mutation in the loop region corresponding to amino acid residues 941-945 is a mutation of the amino acid at position 941 into P.

### Claim 8 (depends on 1)

The protein, or fragment thereof, according to claim 1, wherein the at least one mutation in the loop region corresponding to amino acid residues 941-945 is a mutation of the amino acid at position 944 into P.

### Claim 9 (depends on 1)

The protein, or fragment thereof, according to claim 1, wherein the mutation at position 892 is a mutation into P.

### Claim 10 (depends on 1)

The protein, or fragment thereof, according to claim 1, wherein the mutation at position 614 is a mutation into N or G.

### Claim 11 (depends on 1)

The protein, or fragment thereof, according to claim 1, wherein the mutation at position 532 is a mutation into P.

### Claim 12 (depends on 1)

The protein, or fragment thereof, according to claim 1, wherein the mutation at position 572 is a mutation into I.

### Claim 13 (depends on 1)

The protein, or fragment thereof, according to claim 1, comprising an amino acid sequence wherein the amino acid at position 892 is proline (P), the amino acid at position 614 is glycine (G), the amino acid at position 942 is proline (P) and/or the amino acid at position 944 is proline (P).

### Claim 14 (depends on 1)

The protein, or fragment thereof, according to claim 1, further comprising a deletion of the furin cleavage site.

### Claim 15 (depends on 14)

The protein, or fragment thereof, according to claim 14, wherein the deletion of the furin cleavage site comprises a mutation of the amino acid at position 682 into S and/or a mutation of the amino acid at position 685 into G.

### Claim 16 (depends on 1)

The protein, or fragment thereof, according to claim 1, further comprising a mutation of the amino acids at position 986 and/or 987 into P.

### Claim 17 (depends on 1)

The protein according to claim 1, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5-194 and SEQ ID NO: 197-418, SEQ ID NO: 420 and SEQ ID NO: 421, or a fragment thereof.

### Claim 18 (depends on 1)

The protein, or fragment thereof, according to claim 1, wherein the protein, or fragment thereof, does not comprise a signal peptide or a tag sequence.

### Claim 19 (depends on 1)

The protein, or fragment thereof, according to claim 1, comprising a truncated S2 domain.

### Claim 20 (depends on 18)

The protein, or fragment thereof, according to claim 18 wherein the transmembrane and cytoplasmic domain have been removed.

### Claim 21 (depends on 18)

The protein, or fragment thereof, according to claim 18, wherein a heterologous trimerization domain has been linked to the truncated S2 domain.

### Claim 22 (depends on 21)

The protein, or fragment thereof, according to claim 21, wherein the heterologous trimerization domain is a foldon domain comprising the amino acid sequence of SEQ ID NO:4.

### Claim 23 (depends on 1)

Nucleic acid molecule encoding a protein, or fragment thereof, according to claim 1.

### Claim 24 (depends on 23)

Nucleic acid according to claim 23, wherein the nucleic acid molecule is DNA or RNA.

### Claim 25 (depends on 23)

Vector comprising a nucleic acid according to claim 23.

### Claim 26 (depends on 25)

Vector according to claim 25, wherein the vector is a human recombinant adenoviral vector.

### Claim 27 (depends on 1)

A composition comprising a protein according to claim 1.

### Claim 28 (depends on 1)

A vaccine against COVID-19 comprising a protein, or fragment thereof, according to claim 1.

### Claim 29 (depends on 28)

A method for vaccinating a subject against COVID-19, the method comprising administering to the subject a vaccine according to claim 28.

### Claim 30 (depends on 27)

A method for reducing infection and/or replication of SARS-COV-2 in a subject, comprising administering to the subject a composition according to claim 27.

### Claim 31 (depends on 23)

An isolated host cell comprising a nucleic acid according to claim 23.

### Claim 32 (depends on 23)

An isolated host cell comprising a recombinant human adenovirus of serotype 26 comprising a nucleic acid according to claim 23.
